136 related articles for article (PubMed ID: 12821587)
21. Drug-eluting stents are here--now what? Implications for clinical practice and health care costs.
Hirshfeld JW; Wilensky RL
Cleve Clin J Med; 2004 Oct; 71(10):825-8. PubMed ID: 15529488
[No Abstract] [Full Text] [Related]
22. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
[TBL] [Abstract][Full Text] [Related]
23. Hybrid coronary revascularization in the era of drug-eluting stents.
Murphy GJ; Bryan AJ; Angelini GD
Ann Thorac Surg; 2004 Nov; 78(5):1861-7. PubMed ID: 15511503
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
25. Drug-eluting stents: from evidence to policy.
Marchetti M
Expert Rev Med Devices; 2004 Sep; 1(1):49-63. PubMed ID: 16293010
[TBL] [Abstract][Full Text] [Related]
26. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
Messori A; Trippoli S
Heart; 2009 May; 95(10):847. PubMed ID: 19401286
[No Abstract] [Full Text] [Related]
27. Engineering aspects of stents design and their translation into clinical practice.
Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A
Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159
[TBL] [Abstract][Full Text] [Related]
28. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
29. Vascular radiation in a drug-eluting stent world: it's not over till it's over.
Teirstein PS; King S
Circulation; 2003 Jul; 108(4):384-5. PubMed ID: 12885730
[No Abstract] [Full Text] [Related]
30. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
[TBL] [Abstract][Full Text] [Related]
31. [Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK].
Silber S; Borggrefe M; Böhm M; Hoffmeister HM; Dietz R; Ertl G; Heusch G
Clin Res Cardiol; 2008 Aug; 97(8):548-63. PubMed ID: 18726643
[No Abstract] [Full Text] [Related]
32. The impact of Sirolimus Eluting stents in interventional cardiology.
Di Mario C; Griffiths H; O'Rourke B; Kaddoura S
Int J Cardiol; 2004 Jun; 95(2-3):117-21. PubMed ID: 15193808
[No Abstract] [Full Text] [Related]
33. Drug-eluting stents: meta-analysis in diabetic patients.
Scheen AJ; Warzée F; Legrand VM
Eur Heart J; 2004 Dec; 25(23):2167-8; author reply 2168-9. PubMed ID: 15571834
[No Abstract] [Full Text] [Related]
34. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
[TBL] [Abstract][Full Text] [Related]
35. Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.
Chong PH; Cheng JW
Ann Pharmacother; 2004 May; 38(5):845-52. PubMed ID: 15039482
[TBL] [Abstract][Full Text] [Related]
36. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
37. Can we afford to eliminate restenosis? Can we afford not to?
Greenberg D; Bakhai A; Cohen DJ
J Am Coll Cardiol; 2004 Feb; 43(4):513-8. PubMed ID: 14975456
[TBL] [Abstract][Full Text] [Related]
38. Drug-eluting stents: a pharmacoclinical perspective.
Thomas MK; Gupta YK
Natl Med J India; 2006; 19(4):195-9. PubMed ID: 17100106
[TBL] [Abstract][Full Text] [Related]
39. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).
Serruys PW; Lemos PA; van Hout BA;
Heart; 2004 Sep; 90(9):995-8. PubMed ID: 15310681
[No Abstract] [Full Text] [Related]
40. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
